Home / Themes / MedTech Long '25: Neuromodulation & Neurotechnology Devices
MedTech Long '25: Neuromodulation & Neurotechnology Devices (view performance)
Last updated
Theme thesis · 2/5 sections · Tickers 0 with notes · 9 pending
Bull / Bear Details has the investment thesis and bull/bear points. Overview is monitoring guidance (hiring, forums, second-order trends, search keywords, Google Trends, datasets).
Bull / Bear DetailsThis basket is exposed to the growing clinical and policy momentum around non-pharmaceutical neurological treatment, supported by RFK's emphasis on brain health
Thesis
This basket is exposed to the growing clinical and policy momentum around non-pharmaceutical neurological treatment, supported by RFK's emphasis on brain health, chronic care, and drug alternatives. With Trump-era CMS boosting Medicare Advantage payments and regulatory fast-tracking of breakthrough neurotechnologies, these companies are well-positioned to capitalize on demand for nerve repair, brain stimulation, seizure intervention, and neuro-oncology applications.
Bull case
RFK and CMS are promoting brain-first, non-drug care: The administration supports access to neuromodulation and brain-based therapy alternatives to traditional psychiatric drugs
CMS reimbursement and MA growth support procedure volume: CVRX, STIM, and NPCE benefit from increased MA payments and broader procedural coverage for neuro devices
FDA is accelerating neurodevice approvals: Barostim (CVRX) and TMS platforms (STIM) are seeing faster review and commercialization under Trump's pro-innovation FDA approach
Bear case
Neurotech remains niche and underpenetrated: Despite policy support, real-world physician adoption and reimbursement could lag expectations.
Procedural volumes may fall in recession: Elective neuro procedures are vulnerable to macro pressures and insurance churn.
Policy support may not translate to revenue: Regulatory backing and media buzz may not immediately lead to scaled commercial success or profitability.
Key Metrics
| Metric | Cadence | What It Signals | Update Source |
|---|---|---|---|
| Medicare Advantage neuroprocedure volumes | Quarterly | Indicates coverage-driven demand trends for devices like CVRX, NPCE, and STIM. | Google_Sheets |
| Hospital procedure adoption and CPT reimbursement rates | Quarterly | Reflects clinical uptake and payer willingness to support neuromodulation therapies. | Google_Sheets |
| FDA breakthrough and device approval activity | Monthly | Measures regulatory velocity for novel neurotechnologies (e.g., TMS, nerve repair). | Google_Sheets |
Constituents
- ANGOT3· no notes yet
- ARAYT3· no notes yet
- AXGNT3· no notes yet
- BVUST3· no notes yet
- BWAYT3· no notes yet
- CVRXT3· no notes yet
- NPCET3· no notes yet
- OBIOT3· no notes yet
- STIMT3· no notes yet